[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fred Hutchinson Cancer Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":546},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,78,0,25,[9,43,64,89,111,138,161,179,208,228,249,267,286,305,324,343,361,378,401,423,443,465,484,505,527],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100603814","telephone-based-coaching-sessions-tac-to-improve-advance-care-planning-participation-in-advanced-cancer-patients-and-their-support-person-100603814",false,"NCT07141407","Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Support Person","Community-Engaged Pilot Testing of Talking About Cancer (TAC) to Improve Engagement in Advance Care Planning","Inclusion Criteria:\n\n* PATIENT: Current diagnosis of stage III or IV cancer\n* PATIENT: Able to provide informed consent\n* PATIENT: Fluent in English or Spanish\n* PATIENT: Have access to a telephone, computer, or mobile device\n* CAREGIVER (SUPPORT PERSON): Person patient indicates provides support\n* CAREGIVER (SUPPORT PERSON): English or Spanish speaking\n* CAREGIVER (SUPPORT PERSON): 18 years of age or older\n* CAREGIVER (SUPPORT PERSON): Able to provide informed consent\n\nExclusion Criteria:\n\n* PATIENT: Too ill or weak to complete the interviews (as judged by the interviewer)\n* PATIENT: Receiving hospice at the time of enrollment\n* PATIENT: Younger than age 18",true,"ALL","18 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical trial studies whether telephone-based coaching sessions, Talking About Cancer (TAC), work to improve engagement in advance care planning (ACP) in patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and their support person. Participation in ACP, which includes having end of life (EOL) care conversations and completing advance directives (e.g., living will, health care proxy, do not resuscitate order), improves quality EOL care. Despite this, less than half of patients with advanced cancer have EOL care conversations or complete advance directives. TAC coaching sessions are delivered by a social worker over the phone. They are designed to help patients and their support person communicate about ACP, manage the distress these conversations can cause, and participate in the process of ACP with a clear action plan of having goals-of-care conversations and completing advance directives. This may be an effective way to improve ACP participation in advanced cancer patients and their support person.",[28,29],"Advanced Malignant Solid Neoplasm","Hematopoietic and Lymphatic System Neoplasm","RECRUITING","2026-08-20",{"date":33,"type":34},"2026-08-21","ACTUAL",{"date":36,"type":34},"2026-04-08",{"date":38,"type":22},"2026-12-14",{"name":40,"class":41},"Fred Hutchinson Cancer Center","OTHER",3,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100515831","phase-2-belumosudil-for-the-pre-emptive-treatment-of-patients-with-chronic-graft-versus-host-disease-100515831","NCT05996627","Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease","Randomized Phase II Study of Belumosudil vs. Placebo for Preemptive Treatment of Chronic Graft Versus Host Disease","Inclusion Criteria:\n\n* At least one diagnostic or distinctive cGVHD manifestation(s), with a clinical diagnosis of cGVHD,but patients do not need to meet National Institute of Health (NIH) criteria for cGVHD\n* If eye involvement only, cGVHD must be confirmed on exam by an ophthalmologist or optometrist\n* No new immune suppressive therapy added within preceding 2 weeks prior to study enrollment for any indication\n\n  * Continuation of agents previously given as either GVHD prophylaxis or acute\u002Flate acute GVHD therapy are permitted. Modification of dose of these agents for targeting of therapeutic drug levels is permitted, as are decreases in existing prednisone or prednisone equivalent dose based on routine clinical tapering practices. Increases in prednisone or prednisone equivalents are not allowed in the 2 weeks prior to enrollment\n* Age 18 and older\n* Karnofsky performance score \\>= 70\n* Able to take oral medications\n* Signed informed consent\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\\\u003C 3 x upper limit of normal (ULN)\n* Total bilirubin =\\\u003C 1.5 x ULN, unless due to Gilbert's disease\n* Glomerular filtration rate (estimated glomerular filtration rate \\[eGFR\\]) \\>= 30 mL\u002Fmin\u002F1.73 m\\^2\n* Female subjects of childbearing potential have a negative serum or urine pregnancy test at screening. Females of childbearing potential are defined as sexually mature females without prior hysterectomy or who have had any evidence of menses in the past 12 months. However, females who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti-estrogens, or ovarian suppression\n* Sexually active females of childbearing potential enrolled in the study must agree to use two forms of accepted methods of contraception during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes:\n\n  * Intrauterine device (IUD) plus one barrier method\n  * Stable doses of hormonal contraception for at least 3 months (eg, oral, injectable, implant, transdermal) plus one barrier method\n  * 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gel that contain a chemical to kill sperm)\n  * Surgical sterilization (tubal ligation)\n  * A vasectomized partner\n* For male subjects who are sexually active and who are partners of females of childbearing potential: Agreement to use two forms of contraception as per above and to not donate sperm during the treatment period and for at least 3 months after the last dose of study drug\n* No evidence of active malignancy\n\nExclusion Criteria:\n\n* Any systemic immune suppressive treatment for cGVHD (topical or local therapies are allowed)\n* Plan to start systemic immune suppressive therapy for cGVHD or increase steroid dose within 14 days after planned start of study medication\n* 0.25 mg\u002Fkg\u002Fday or higher prednisone or prednisone equivalent dose at time of screening\n* History of non-compliance that in the investigator's opinion would interfere with study participation\n* Uncontrolled psychiatric illness\n* Female subject who is pregnant or breast feeding\n* Previous therapy with belumosudil\n* Known allergy\u002Fsensitivity to belumosudil or any other ROCK2 inhibitor\n* Treatment with another investigational agent within 28 days (or 5 half-lives, whichever is greater) of enrollment",{"count":51,"type":22},82,[53],"PHASE2","This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease. Chronic graft versus host disease remains a major complication of stem cell transplantation and can involve multiple organ systems. Belumosudil is a ROCK2 selective inhibitor that works to reduce the immune system response causing the chronic graft versus host disease. Giving belumosudil may better treat patients with chronic graft versus host disease and prevent the need for starting additional immune suppressive medications.",[56],"Chronic Graft Versus Host Disease",{"date":33,"type":34},{"date":59,"type":34},"2023-12-06",{"date":61,"type":22},"2028-11-30",{"name":40,"class":41},5,{"id":65,"slug":66,"hasResults":12,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":23,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},"100610518","phase-2-ruxolitinib-before-during-and-after-hematopoietic-cell-transplant-in-older-patients-with-myelofibrosis-and-myelodysplastic-syndromemyeloproliferative-neoplasm-overlap-syndromes-100610518","NCT07228624","Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome\u002FMyeloproliferative Neoplasm Overlap Syndromes","Peri-Hematopoietic Cell Transplantation Ruxolitinib in Patients With Myelofibrosis and Myelodysplastic Syndrome\u002FMyeloproliferative Neoplasm Overlap Syndromes","Inclusion Criteria:\n\n* PART 1 JAK INHIBITOR ADMINISTRATION: Age 18-75 years\n\n  * Patients \\> 75 must be considered an HCT candidate, meet all protocol criteria and have comorbidity score =\\\u003C 3 and Karnofsky performance status (KPS) \\> or = to 90. Patients. \\> 75 who do not meet these criteria may be presented at PCC for consensus exception\n* PART 1 JAK INHIBITOR ADMINISTRATION: Disease criteria\n\n  * Diagnosis of primary or secondary MF as defined by the 2022 World Health Organization classification system or the International Consensus Classification for Myeloid and Acute Leukemias\n  * Diagnosis of an MDS\u002FMPN overlap syndrome as defined by the 2022 World Health Organization\n* PART 1 JAK INHIBITOR ADMINISTRATION: Ability to understand and the willingness to sign a written informed consent document\n* PART 1 JAK INHIBITOR ADMINISTRATION: Patient must be a potential HCT candidate as assessed by the consenting physician\n* PART 1 JAK INHIBITOR ADMINISTRATION: Patient must be agreeable to taking a JAK-inhibitor (ruxolitinib preferred) for at least 8 consecutive weeks immediately prior to conditioning and be willing to take ruxolitinib 5mg BID starting from day -4 prior to and continuing until 12 months post-transplant as tolerated followed by a 6-month taper.\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Meeting criteria for Part 1 at time of initiation of JAK-inhibitor, including the ability to understand and willingness to sign a written informed consent. Patients arriving to our institution for HCT and not enrolled in Part 1 may still be enrolled in Part 2 if Part 1 criteria are met. These patients will have Part 1 endpoints transcribed from their medical records\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Received a JAK-inhibitor for at least 8 weeks immediately prior to conditioning and be willing to take Rux from day -4 at the 5mg BID dose until 12 months post-transplant as tolerated followed by a 6 month taper\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Performance status score\n\n  * Karnofsky ≥ 70 or \\> 90 for patients \\> 75 years old\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: HCT-CI Score \\\u003C 8; if patient is \\> 75 years old HCT-CI \\\u003C 3\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Calculated creatinine clearance using the Cockcroft-Gault formula or 24-hour urine creatinine clearance must be \\> 60 ml\u002Fmin\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Total serum bilirubin must be \\\u003C 3mg\u002FdL unless the elevation is thought to be due to Gilbert's disease or hemolysis\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Transaminases must be \\\u003C 3 x the upper limit of normal\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Patients with clinical or laboratory evidence of liver disease will be evaluated for the cause of liver disease, its clinical severity in terms of liver function, and the degree of portal hypertension. Patients with fulminant liver failure, cirrhosis with evidence of portal hypertension or bridging fibrosis, alcoholic hepatitis, hepatic encephalopathy, or correctable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin \\> 3mg\u002FdL, and symptomatic biliary disease will be excluded\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Diffusion capacity of lung for carbon monoxide (DLCO) corrected \\> 60% normal. Patient may not be on oxygen\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Left ventricular ejection fraction \\> 40%\n* DONOR: Human leukocyte antigen (HLA)-matched sibling donor\n* DONOR: 10 of 10 HLA-matched unrelated donor\n* DONOR: 9 of 10 allele or antigen mismatched unrelated donor\n* DONOR: Peripheral blood is preferred over bone marrow\n* DONOR: Matched unrelated donors may be preferred over siblings if the unrelated donor is \\\u003C 30 years and the sibling is \\> 60 years. However, sibling donors \\\u003C 70 should be preferred over mismatched unrelated donors\n\nExclusion Criteria:\n\n* PART 1 JAK INHIBITOR ADMINISTRATION: Contraindication to receiving ruxolitinib including patients who have known hypersensitivity to JAK inhibitors and excipients\n* PART 1 JAK INHIBITOR ADMINISTRATION: History of prior allogeneic transplant\n* PART 1 JAK INHIBITOR ADMINISTRATION: Leukemic transformation (\\> 20% blasts)\n* PART 1 JAK INHIBITOR ADMINISTRATION: Uncontrolled viral, bacterial, or fungal infection despite being on therapy\n* PART 1 JAK INHIBITOR ADMINISTRATION: History of HIV infection\n* PART 1 JAK INHIBITOR ADMINISTRATION: History of untreated tuberculosis (TB)\n* PART 1 JAK INHIBITOR ADMINISTRATION: Pregnant or breastfeeding\n* PART 1 JAK INHIBITOR ADMINISTRATION: Patients with history of myocardial infarction (MI), cerebrovascular accident (CVA) or unprovoked pulmonary embolism (PE)\u002Fdeep vein thrombosis (DVT) in the past 6 months\n* PART 1 JAK INHIBITOR ADMINISTRATION: Secondary malignancy in last 5 years with \\> 20% risk of relapse\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Contraindication to receiving ruxolitinib including patients who have known hypersensitivity to JAK inhibitors and excipients\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: History of prior allogeneic transplant\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Leukemic transformation (\\> 20% blasts)\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Uncontrolled viral or bacterial infection at the time of transplant data review and consent conference\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Active or recent (prior 6 month) invasive fungal infection without infectious disease (ID) consult and approval\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: History of HIV infection\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: History of untreated TB\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Requiring supplemental oxygen\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Pregnant or breastfeeding\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Secondary malignancy in last 5 years with \\> 20% risk of relapse\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Patients with a history of MI, CVA, or unprovoked PE\u002FDVT in the past 6 months\n* PART 2 ALLOGENEIC STEM CELL TRANSPLANT: Patients without an HLA-identical sibling donor, 10 of 10 HLA-matched or 9 of 10 mismatched unrelated donor","75 Years",{"count":73,"type":22},50,[53],"This phase II trial tests the effect of adding ruxolitinib to standard graft versus host disease (GVHD) prevention in treating older patients with myelofibrosis (MF) or myelodysplastic syndrome\u002Fmyeloproliferative neoplasm (MDS\u002FMPN) overlap syndromes before, during, and after a donor (allogeneic) hematopoietic cell transplant (HCT). Allogeneic HCT is a procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a genetically similar, but not identical donor. Giving chemotherapy, such as cytoxan and busulfan or fludarabine and melphalan, before a donor transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. However, sometimes the transplanted cells from a donor can attack the body's normal cells (called GVHD). Giving standard prevention (prophylaxis) therapies, such as tacrolimus and methotrexate, after the transplant may stop this from happening. Methotrexate, a type of antifolate, is in a class of medications called antimetabolites. Methotrexate stops cells from using folic acid to make deoxyribonucleic acid and may kill cancer cells. Tacrolimus is used to help reduce the risk of rejection by the body of organ and bone marrow transplants. Ruxolitinib, a type of Janus-associated kinase (JAK) inhibitor, blocks a protein called JAK, which may help keep abnormal blood cells or cancer cells from growing. It may also lower the body's immune response and prevent the development of GVHD. Giving ruxolitinib before, during and after allogeneic HCT in addition to standard GVHD prophylaxis may be safe, tolerable and effective in preventing GVHD and improving outcomes in older patients with MF or MDS\u002FMPN overlap syndrome.",[77,78,79],"Myelodysplastic\u002FMyeloproliferative Neoplasm","Primary Myelofibrosis","Secondary Myelofibrosis","2026-08-17",{"date":82,"type":34},"2026-08-19",{"date":84,"type":34},"2026-02-04",{"date":86,"type":22},"2030-09-01",{"name":40,"class":41},1,{"id":90,"slug":91,"hasResults":12,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":23,"phases":98,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100592630","improving-uptake-of-surveillance-in-colorectal-cancer-survivors-through-navigation-and-web-education-100592630","NCT06995924","Improving Uptake of Surveillance in Colorectal Cancer Survivors Through Navigation and Web Education","A Pilot Trial to Evaluate the Effectiveness of Navigation, Interactive Web Education, or the Combination of Both to Promote Guideline-Concordant Colorectal Cancer Surveillance Care","Inclusion Criteria:\n\n* Age ≥ 18 due to disease and clinic population\n* Stage I-III CRC survivor within 3 months post-surgical resection\n* Being seen at a participating clinic\n* Ability to understand and complete surveys in English",{"count":97,"type":22},75,[25],"This pilot clinical trial looks at whether patient navigation services, an interactive web education intervention, called Current Together After Cancer (CTAC), or both navigation and CTAC works to improve the uptake of surveillance in patients with stage I-III colorectal cancer (CRC). Post-treatment surveillance is critical to detect recurrence early, yet many CRC survivors do not receive recommended surveillance care. Surveillance is a complex process that includes laboratory tests, cross-sectional imaging, and endoscopic procedures. Patient navigation services, interactive web education, or a combination of both may improve surveillance care for patients with stage I-III colorectal cancer.",[101,102,103],"Stage I Colorectal Cancer AJCC v8","Stage II Colorectal Cancer AJCC v8","Stage III Colorectal Cancer AJCC v8",{"date":82,"type":34},{"date":106,"type":34},"2025-11-17",{"date":108,"type":22},"2027-03-31",{"name":40,"class":41},2,{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":120,"phases":4,"briefSummary":121,"conditions":122,"keywords":126,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":88},"100586961","development-of-measures-to-screen-for-financial-hardship-in-alzheimers-disease-and-dementia-100586961","NCT06922188","Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia","AD\u002FADRD","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* One of the following:\n\n  * Clinical diagnosis of Alzheimer's disease or related dementia\n  * Being a caregiver to individuals with clinical diagnosis of Alzheimer's disease or related dementia\n* Able to read and speak English or Spanish\n* Able to provide informed consent\n* Residing in the United States\n\nExclusion Criteria:\n\n• Cognitive impairment precluding informed consent",{"count":119,"type":22},2460,"OBSERVATIONAL","Alzheimer's Disease and related dementias (AD\u002FADRD) are common and debilitating conditions. Financial hardship, a multidimensional construct of financial strain, financial stress and asset depletion, is common in AD\u002FADRD due to exorbitant out-of-pocket spending such as for long-term care, lower work productivity and income for their caregivers that can last for decades after disease onset, and difficulty deciding between nursing home care or home-based care while negotiating insurance coverage. People from historically marginalized groups can experience a double disparity with fewer financial resources to manage AD\u002FADRD and a greater risk of AD\u002FADRD. Screening for financial hardship in AD\u002FADRD is key for addressing the needs of patients and caregivers but critical barriers include a lack of suitable screening measures. Current measures are very general and meant for people without chronic medical conditions or are specific to other diseases. To fill this gap, this study will create a suite of measures that can screen for financial hardship in people with AD\u002FADRD and their families and caregivers. The measures will include a set to assess caregiver burden; a set to assess patient hardship as reported by the caregiver for patients who cannot report for themselves; and a set of patient-reported measures for patients that are able to report for themselves. To create these financial hardship screening measures, the project will conduct the following aims. Aim 1- Develop financial hardship screening measures for Alzheimer's Disease and related dementias: Using interviews with both caregivers and people with AD\u002FADRD, key indicators of financial hardship that are unique to AD\u002FADRD and the point in the lifespan in which it occurs will be identified. The ways that social and caregiver network size affect financial hardship will also be explored. Using the interviews and previous measures, preliminary measures will be created and will be reviewed by experts and a patient and caregiver advisory board. Aim 2- Create item response theory-based screening measures for financial hardship measures in Alzheimer's Disease and related dementias: Large samples of people with AD\u002FADRD (n=1000) and caregivers (n=1000) will be surveyed and item response theory will be used to evaluate and revise the measures and create scoring algorithms. A sample of additional caregivers matched to primary caregivers (n=400) will also be recruited to evaluate interrater reliability of the measures. Aim 3- Evaluate the financial hardship measures across patient and caregiver populations: Using the sample from Aim 2 and item response theory, we will evaluate the financial hardship screening measures across the following groups to ensure they are unbiased and reflect true differences: race\u002Fethnicity; patient comorbidities; stage of AD\u002FADRD; caregiver relationship; social network size; number of caregivers; financial support provided; and caregiver's own health status (disability, comorbidities). The resulting measures will improve identification of financial hardship in AD\u002FADRD.",[123,124,125],"Financial Hardship","Alzheimer's Disease (AD)","Alzheimer's Disease and Related Dementia (ADRD)",[127,128,129,130,131],"Social Determinants of Health","Financial Toxicity","Financial Burden","Dementia","Alzheimers Disease",{"date":82,"type":34},{"date":134,"type":34},"2025-03-31",{"date":136,"type":22},"2029-12-18",{"name":40,"class":41},{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":148,"conditions":149,"keywords":153,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":110},"100539045","high-intensity-exercise-and-high-fiber-diet-for-immunotherapy-outcomes-in-melanoma-patients-the-duo-trial-100539045","NCT06298734","High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial","Modulating Immune-Microbiome Axis Through High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial","Inclusion Criteria:\n\n* Age ≥18 years.\n* Histologically diagnosed with melanoma.\n* Having been or newly receiving immunotherapy for at least one month.\n* Having a plan to continue immunotherapy for at least 8 weeks at the time of recruitment.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2, indicating the ability to fulfill physical fitness and function assessments.\n* Ability to understand and willingness to provide informed consent.\n\nExclusion Criteria:\n\n* Participating in ≥ 150 minutes of moderate-to-vigorous aerobic exercise per week over the past month.\n* Consuming ≥ 30 grams\u002Fday of dietary fiber over the past month.\n* Having chronic medical conditions that are clinically unstable or uncontrolled with medications, deemed high-risk for exercise. These include but are not limited to unstable cardiac diseases, uncontrolled diabetes, and bone metastases with imminent risk of fracture.\n* Having a high risk for noncompliance with study procedures. This will be determined by the study team based on the history of missed oncology appointments (i.e., ≥3 no-shows in 6 months) and poor responsiveness during recruitment (i.e., ≥3 unreturned contacts).\n* Patients who are non-English speaking and cannot complete the participant surveys.",{"count":146,"type":22},40,[25],"The purpose of this study is to determine whether high-intensity exercise and high-fiber diet are feasible and improve various health outcomes among participants with advanced melanoma receiving immunotherapy.\n\nThe names of the groups in this research study are:\n\n* High-Intensity Exercise (EX)\n* High-fiber Diet (DT)\n* Combined High-Intensity Exercise and High-Fiber Diet (COMB)\n* Attention Control (AC)",[150,151,152],"Melanoma (Skin)","Skin Cancer","Advanced Melanoma",[154,151,152],"Melanoma",{"date":82,"type":34},{"date":157,"type":34},"2024-07-01",{"date":159,"type":22},"2027-07-31",{"name":40,"class":41},{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":170,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":178,"locationsCount":88},"100527284","a-digital-smoking-cessation-intervention-for-helping-american-indians-and-alaska-natives-quit-smoking-indigequit-trial-100527284","NCT06145763","A Digital Smoking Cessation Intervention for Helping American Indians and Alaska Natives Quit Smoking, IndigeQuit Trial","Digital Smoking Cessation Intervention for Nationally-Recruited American Indians and Alaska Natives: A Full-Scale Randomized Controlled Trial (IndigeQuit)","Inclusion Criteria:\n\n* Self-identify as American Indian or Alaska Native, either alone or in combination with other races\n* Age 18 and older\n* Has smoked daily for the past year\n* Interest in quitting smoking within the next 30 days\n* Willing to be randomly assigned to either app\n* Have daily access to their own Android or iPhone\n* Able to download a smartphone app\n* Be willing and able to read English\n* Not currently or within past 30 days using other smoking cessation behavioral interventions or smoking cessation pharmacotherapies\n* Have never participated in our prior research\n* Have no other household or family member participating\n* Being willing to complete the 3, 6, and 12-month follow-up assessments\n* Providing email, phone number(s), and mailing address\n* Living off United States (US) AI\u002FAN tribal reservations or living on five Northern Plains tribal reservations from whom we would obtain approvals to recruit\n\nExclusion Criteria:\n\n* Currently (i.e., within past 30 days) using other smoking cessation behavioral interventions\n* Has participated in our prior research trials\n* Has used the National Cancer Institute's (NCI's) QuitGuide app\n* Not willing to complete a follow-up survey at 3, 6, and 12 months post-randomization\n* Not providing email, phone number(s), and mailing address",{"count":169,"type":22},776,[25],"This clinical trial compares a new smoking cessation smartphone application (app) (IndigeQuit) to an existing smarphone app (National Cancer Institute \\[NCI\\] QuitGuide) for helping American Indians and Alaska Natives (AI\u002FANs) quit smoking. Compared to other racial\u002Fethnic groups, AIANs have 6 times higher rates of developing smoking-related cancers, including lung cancer. Commercial cigarette smoking accounts for half of all deaths among AIANs nationwide. AIANs' often lack of access to smoking cessation interventions, which may be due to inequities in the healthcare system, lack of health insurance, living in rural areas, systemic racism, and historical trauma. There is also a lack of effective smoking cessation interventions for AIANs. Smartphone apps have the potential to deliver a low-cost smoking cessation intervention with wide reach to AIANs. Apps require no in-person delivery and no provider training, do not require integration into complex hospital systems, can be freely accessed on an app store, and are available at any time and any place. IndigeQuit is a behavioral intervention designed to help adults stop smoking by teaching skills for coping with smoking urges, staying motivated, and preventing relapse. The IndigeQuit app intervention may be more effective than the currently available NCI QuitGuide app at helping AIANs quit smoking.",[173],"Cigarette Smoking-Related Carcinoma",{"date":82,"type":34},{"date":176,"type":34},"2025-07-03",{"date":61,"type":22},{"name":40,"class":41},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":23,"phases":188,"briefSummary":189,"conditions":190,"keywords":195,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":207},"100402096","mobile-health-application-pact-to-improve-engagement-in-advance-care-planning-100402096","NCT04515810","Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning","Planning Advance Care Together (PACT) to Improve Engagement in Advance Care Planning","Inclusion Criteria:\n\n* PATIENT: Diagnosis of poor prognosis advanced cancer defined as locally advanced or metastatic solid cancer and\u002For disease progression following at least first line systemic therapy and\u002For relapsed or refractory hematologic cancer.\n* PATIENT: Have internet access through a computer or a mobile device; the principal investigator (PI) will ensure that those who have access to a computer or mobile device have access to a computer or mobile device with internet access to ensure they can complete study procedures.\n* PATIENT: The ability to provide informed consent.\n* PATIENT: Identification of a loved support person if one is available; patients who are unable to identify a support person willing to participate with them will be allowed to continue in the study on their own.\n* PATIENT: 18 years of age or older.\n* SUPPORT PERSON: The person (family member or friend) whom the patient indicates being a support person.\n* SUPPORT PERSON: English speaking.\n* SUPPORT PERSON: 18 years of age or older and able to provide informed consent.\n* PROVIDER: Current clinical practice and\u002For research with advanced cancer patients.\n* PROVIDER: A history of 3+ years working with advanced cancer patients.\n* PROVIDER: 18 years of age or older. Providers across disciplines (e.g., social work, oncology) will be enrolled.\n\nExclusion Criteria:\n\n* PATIENT: Not fluent in English.\n* PATIENT: Severely cognitively impaired (as measured by Short Portable Mental Status Questionnaire scores of \\>= 6) to be delivered by trained study research staff during screening.\n* PATIENT: Too ill or weak to complete the interviews (as judged by the interviewer).\n* PATIENT: Currently receiving hospice at the time of enrollment.\n* PATIENT: Children and young adults under age 18.",{"count":187,"type":22},400,[25],"This clinical trial tests a new mobile health application (app) called Planning Advance Care Together (PACT) to help people with cancer talk about and plan for advance care planning (the care they would want if they were unable to communicate) with their loved ones and doctors. The development of the PACT mobile app may help future patients incorporate their social network (typically, but not exclusively, family) into the advance care planning process.",[191,192,193,194],"Locally Advanced Malignant Solid Neoplasm","Metastatic Malignant Solid Neoplasm","Recurrent Hematologic Malignancy","Refractory Hematologic Malignancy",[196,197,198,199],"Advance Care Planning","Advance Directives","End-of-Life","Cancer","2026-08-14",{"date":80,"type":34},{"date":203,"type":34},"2025-02-18",{"date":205,"type":22},"2027-08-31",{"name":40,"class":41},4,{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":23,"phases":216,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":88},"100609039","phase-2-rifaximin-versus-no-intervention-for-the-treatment-of-iga-monoclonal-gammopathy-of-undetermined-significance-100609039","NCT07209371","Rifaximin Versus No Intervention for the Treatment of IgG\u002FIgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance","Rifaximin Versus No Intervention in Patients With IgG\u002FIgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Ability to understand and willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of potential study participants\n* Clinical diagnosis of IgG\u002FIgA (non-IgM) monoclonal gammopathy of undetermined significance (MGUS) based on International Myeloma Working Group (IMWG)-2014 criteria (Rajkumar et al, Lancet Oncology, 2014). It is recognized that not all patients with clinical diagnosis of MGUS undergo bone marrow biopsy. Bone marrow biopsy confirmation will not be required if not clinically indicated per treating provider\n* Agree to use adequate contraception\n\n  * For women of child-bearing potential: prior to study entry and for the duration of study participation\n  * For men: prior to study entry, for the duration of study participation, and one month after completion of rifaximin administration (for men)\n* No antibiotic use in the preceding 2 weeks\n\nExclusion Criteria:\n\n* Participants who are receiving other investigational agents\n* Pregnant women\n* Known hypersensitivity to rifaximin\n* Another concurrent malignancy requiring active therapy",{"count":73,"type":22},[53],"This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgG\u002FIgA monoclonal gammopathy of undetermined significance (MGUS). Rifaximin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's DNA and may kill cancer cells or precancerous cells like those found with MGUS. Giving rifaximin may kill more precancerous cells in patients with IgG\u002FIgA MGUS.",[219,220],"IgA Monoclonal Gammopathy of Undetermined Significance","Non-IgM Monoclonal Gammopathy of Undetermined Significance","2026-08-13",{"date":80,"type":34},{"date":224,"type":34},"2026-01-22",{"date":226,"type":22},"2028-05-01",{"name":40,"class":41},{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":23,"phases":237,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":88},"100642307","phase-1-fh-wt1-e50-tcr-t-cells-with-azacitidine-for-the-treatment-of-minimal-residual-disease-positive-acute-myeloid-leukemia-100642307","NCT07645469","FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia","Phase I Study of Autologous CD4+ and CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Treatment of MRD-Positive AML","Inclusion Criteria for Leukapheresis:\n\n* LEUKAPHERESIS: Age 18 years or older at the time of enrollment\n* LEUKAPHERESIS: Confirmed diagnosis of AML that is not M3 subtype (acute promyelocytic leukemia \\[APL\\])\n* LEUKAPHERESIS: Human leukocyte antigen (HLA) type HLA-A\\*02:01 confirmed through HLA typing\n* LEUKAPHERESIS: Tissue confirmation of WT1 expression by immunohistochemistry. Confirmation of diagnosis must be or have been performed by internal pathology review of archival biopsy material or other pathologic material at Fred Hutch\u002FUniversity of Washington Medical Center (UWMC)\n* LEUKAPHERESIS: Capable of understanding and willing to provide informed consent\n* LEUKAPHERESIS: Fertile male and female participants must be willing to use an effective contraceptive method before, during, and for at least 4 months after the last FH-WT1-E50 TCR T infusion\n* LEUKAPHERESIS: Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 or Karnofsky Performance Status (KPS) ≥ 60%\n* LEUKAPHERESIS: No immediate plan for allogeneic stem cell transplantation: patients must not have a planned allogeneic hematopoietic stem cell transplant (HCT) within 8 weeks of leukapheresis. Patients may still be considered for HCT in the future but must not have a scheduled transplant at the time of enrollment due to factors including, but not limited to, donor availability, performance status, comorbidities, or patient preference. Patients who subsequently become candidates for HCT (e.g., donor identified or improvement in performance status) may proceed to transplant at the discretion of the treating physician without a mandated waiting period related to study participation\n* LEUKAPHERESIS: Creatinine clearance ≥ 30 ml\u002Fmin by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) or 24-hour urine clearance\n* LEUKAPHERESIS: Total bilirubin \\\u003C 3.0 mg\u002FdL. Participants with suspected Gilbert syndrome may be included if total bilirubin (tBili) \\> 3mg\u002FdL but no other evidence of hepatic dysfunction\n* LEUKAPHERESIS: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C 5 x upper limit of normal (ULN)\n* LEUKAPHERESIS: Participants 60 years of age or older are required to have left ventricular ejection fraction (LVEF) evaluation performed within 60 days prior to enrollment. LVEF may be established with echocardiogram or MUGA scan, and left ejection fraction must be ≥ 35%. Cardiac evaluation for other participants is at the discretion of the treating physician\n\nInclusion Criteria at Start of Treatment:\n\n* START OF TREATMENT: Presence of Measurable Residual Disease (MRD) after induction therapy at the time of screening. Patients must have achieved a morphologic remission (marrow that is at least 10% cellular with \\\u003C 5% blasts on morphologic review) with detectable MRD, regardless of incomplete recovery of neutrophil counts\u002Fless than 1,000\u002Fmm3 (CRi) or platelet counts less than 100,000\u002Fmm3 (CRp). Eligible remission-induction regimens include, but are not limited to, conventional induction chemotherapy (e.g., 7+3 or similar anthracycline\u002Fcytarabine-based regimens) and hypomethylating agent-based combinations (e.g., azacitidine\u002Fvenetoclax).\n\n  * MRD definition:\n\n    * MRD by flow cytometry: defined by any abnormal myeloid blasts identified by flow cytometric analysis. In addition, for patients with NPM1-mutated disease, we will incorporate a clinically validated quantitative NPM1 MRD assay performed at Fred Hutch. For patients with FLT3-ITD-mutated disease, MRD assessment will include a clinically validated FLT3-ITD assay performed at Invivoscribe.\n* START OF TREATMENT: Participants must be willing to undergo serial tumor biopsies and\u002For aspirates for research purposes if safe and feasible at baseline (prior to first T cell infusion), 2-3 weeks after the first T cell infusion, and approximately 2 weeks +\u002F- 1 week after the second infusion (if applicable) (these windows may vary due to manufacturing or clinical reasons). Should there be no marrow tissue that is accessible, participants will still be considered for participation, at the discretion of the investigator. Similarly, should an investigator determine that a marrow assessment cannot be performed safely for clinical reasons, those may be cancelled or rescheduled. Participants must be at least two weeks or five half lives (for small molecules) from last systemic treatment: At least 2 weeks must have passed since any: immunotherapy (for example, T cell infusions, immunomodulatory agents, interleukins, vaccines), or chemotherapy cancer treatment. At least five half-lives must have passed from treatment with small molecules or other investigational agents\n* START OF TREATMENT: ECOG performance status of 0, 1, or 2 or Karnofsky Performance Status (KPS) ≥ 60%\n* START OF TREATMENT: Creatinine clearance ≥ 30 ml\u002Fmin by CKD-EPI or 24-hour urine clearance\n* START OF TREATMENT: Total bilirubin \\\u003C 3.0 mg\u002FdL. Participants with suspected Gilbert syndrome may be included if tBili \\> 3mg\u002FdL but no other evidence of hepatic dysfunction.\n* START OF TREATMENT: Participants 60 years of age or older are required to have left ventricular ejection fraction (LVEF) evaluation performed within 60 days prior to enrollment. LVEF may be established with echocardiogram or MUGA scan, and left ejection fraction must be ≥ 35%. Cardiac evaluation for other participants is at the discretion of the treating physician\n* START OF TREATMENT: Participants with a history of chronic obstructive pulmonary disease (COPD), emphysema, or greater than 30 pack year smoking history should undergo pulmonary function tests (PFTs) and meet the following criteria:\n\n  * Forced expiratory volume in 1 second (FEV1) ≥ 50% of predicted and carbon monoxide diffusing capacity (DLCO) (corrected) ≥ 40% of predicted will be eligible\n\nExclusion Criteria for Leukapheresis:\n\n* LEUKAPHERESIS: Prior solid organ transplant or allogeneic hematopoietic stem cell transplant. Kidney transplant participants will be considered on a case-by-case basis requiring discussion with principal investigator (PI). If the participant has had a kidney transplant, participant must have dialysis access, dialysis plan, supportive nephrologist, willingness to stop transplant immunosuppression, and express understanding that rejection is possible outcome. Dialysis or costs related to transplant kidney will not be supported by the study. Participants having had any other solid organ transplants will be excluded, as will those with any history of allogeneic hematopoietic stem cell transplant\n\nExclusion Criteria at Start of Treatment:\n\n* START OF TREATMENT: Evidence of TET2, ASXL1 or DNMT3a mutations as sole evidence of MRD\n* START OF TREATMENT: Pregnancy, breastfeeding, or expecting to conceive or father children for the duration of the trial through 4 months after last T cell infusion. Participants of childbearing potential must have a negative serum pregnancy test within the 2 weeks (14 days) preceding T cell infusion. Childbearing potential is defined as women who have not been surgically sterilized and who are not post-menopausal (free of menses for at least 1 year)\n* START OF TREATMENT: Active autoimmune disease: Participants with active autoimmune disease requiring immunosuppressive therapy are excluded. Case-by-case exemptions are possible with approval by PI\n* START OF TREATMENT: Unable to generate FH-WT1-E50 TCR T cells for infusions. However, if a lower than planned number of cells is available, the participant will have the option to receive the generated WT1-specific T cells\n* START OF TREATMENT: Corticosteroid therapy at a systemic dose equivalent of \\> 0.5 mg\u002Fkg of prednisone-equivalent per day. The following treatments are permitted: intranasal, inhaled, topical, or local steroid applications; systemic corticosteroids at physiologic doses equivalent to no more than 10 mg\u002Fday prednisone; steroids as premedication for contrast dye allergy\n* START OF TREATMENT: Concurrent use of other investigational anti-cancer agents\n* START OF TREATMENT: Active uncontrolled infection: HIV positive participants on highly active antiretroviral therapy (HAART) with a CD4 count \\> 500 cells\u002Fmm3 are considered controlled, as are individuals with a history of hepatitis C who have successfully completed antiviral therapy with an undetectable viral load, and those with hepatitis B who have, per standard practice, hepatitis well-controlled on medication\n* START OF TREATMENT: Uncontrolled concurrent illness: Participants may not have uncontrolled or concurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* START OF TREATMENT: Known allergic reactions to any of the components of study treatments\n* START OF TREATMENT: Other medical, social, or psychiatric factors that interfere with medical appropriateness and\u002For ability to comply with study, as determined by the PI",{"count":236,"type":22},9,[238],"PHASE1","This phase I trial tests the safety, side effects and best dose of FH-WT1-E50 TCR T cells with azacitidine for the treatment of minimal residual disease (MRD) positive acute myeloid leukemia (AML). T cells are infection fighting blood cells that can kill tumor cells. The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize WT1, a protein on the surface of cancer cells. These WT1-specific T cells may help the body's immune system identify and kill WT1 cancer cells. Azacitidine is in a class of medications called antimetabolites. It works by stopping or slowing the growth of cancer cells. Giving FH-WT1-E50 TCR T Cells with azacitidine may be safe and\u002For effective for the treatment of MRD positive AML.",[241],"Acute Myeloid Leukemia","2026-08-11",{"date":221,"type":34},{"date":245,"type":22},"2026-09-01",{"date":247,"type":22},"2030-07-19",{"name":40,"class":41},{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":23,"phases":257,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":42},"100593851","phase-2-axatilimab-for-sclerotic-chronic-graft-versus-host-disease-100593851","NCT07011810","Axatilimab for Sclerotic Chronic Graft-versus-Host Disease","Axatilimab for Sclerotic Chronic Graft-Versus-Host Disease","Inclusion Criteria:\n\n* Adults aged 18 and older\n* Ability to understand and willingness to sign a written informed consent document\n* Allogeneic stem cell transplant, with active cGVHD requiring systemic treatment. Active cGVHD is defined as the presence of signs and symptoms of cGVHD diagnosed per the 2014 National Institutes of Health (NIH) Consensus Development Project on Criteria for Clinical trials in cGVHD\n* Sclerotic skin score 2-3 or PROM \\\u003C 24 or Joints\u002FFascia score 2-3 due to cGVHD\n* Initial diagnosis of sclerosis within the past 12 months.\n\n  * For example, if a patient is diagnosed with sclerosis on 01\u002F01\u002F2026, they remain eligible through 01\u002F01\u002F2027\n* No new non-corticosteroid systemic immunosuppressive agent within 28 days prior to screening, unless there is a plan to stop them no later than 21 days after the first dose of axatilimab. Receipt of systemic corticosteroids ≤ 1 mg\u002Fkg prednisone or prednisone equivalent daily is allowed at the time of enrollment and may be continued after axatilimab initiation\n* If patient has been previously treated with systemic immunosuppression for sclerosis, one of the following two conditions must be true: (a) the systemic immunosuppressive treatment(s) were given for at least 60 days and the sclerotic cGVHD either did not respond, progressed, or initially improved but has not continued to improve in the last 6 weeks; (b) the systemic immunosuppressive treatment(s) were given for less than 60 days due to lack of sclerotic cGVHD response, sclerotic cGVHD progression, toxicity or logistic reasons and have or will be stopped no later than 21 days after the first dose of axatilimab\n* Karnofsky performance status ≥ 60%\n* Absolute neutrophil count ≥ 1.0 x 10\\^9\u002FL (evaluated during the 28-day screening period)\n* Platelet count ≥ 50 x 10\\^9\u002FL (evaluated during the 28-day screening period) (without transfusion within 2 weeks of study entry)\n* If no suspected or proven liver cGVHD, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN) (evaluated during the 28-day screening period) unless due to Gilbert's disease\n* If no suspected or proven liver cGVHD, total bilirubin ≤ 1.5 x ULN (evaluated during the 28-day screening period) unless due to Gilbert's disease\n* For patients with suspected or documented liver cGVHD, ALT and AST ≤ 5 x ULN (evaluated during the 28-day screening period) unless due to Gilbert's disease\n* For patients with suspected or documented liver cGVHD, total bilirubin ≤ 1.5 x ULN (evaluated during the 28-day screening period) unless due to Gilbert's disease\n* Estimated creatinine clearance ≥ 30 mL\u002Fmin based on the institutional formula\n* Male and female participants of reproductive potential must be willing to employ highly effective and acceptable forms of contraception from screening through 90 days after the last dose of study treatment.\n\n  * Adolescent and adult male patients capable of fathering a child who are non-sterilized and who are not abstinent and intend to be sexually active with a female partner of childbearing potential must use two methods of birth control from the time of screening throughout the total duration of the study intervention treatment period and 90 days after the last dose of study intervention. Male patients should refrain from sperm donation throughout this period\n  * Female patients of childbearing potential who are not abstinent and intend to be sexually active with a non-sterilized male partner must use at least one highly effective method of contraception from the time of screening throughout the total duration of the study intervention treatment period and 90 days after the last dose of study intervention. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Female patients should also refrain from breastfeeding throughout this period\n  * Female subjects of childbearing potential must have a negative serum pregnancy test within 72 hours prior to treatment initiation. Females of childbearing potential are defined as sexually mature females without prior hysterectomy or who have had any evidence of menses in the past 12 months. However, females who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti-estrogens, or ovarian suppression\n\nExclusion Criteria:\n\n* Hospitalization for evaluation or management of an infection within 28 days prior to screening\n* History or other evidence of significant organ dysfunction that would make the patient, in the opinion of the investigator, unsuitable for the study\n* On more than 1 mg\u002Fkg\u002Fday prednisone or prednisone equivalent\n* History of non-compliance\n* History or other evidence of uncontrolled psychiatric illness that that would limit compliance with study requirements\n* Receipt of an investigational agent within 28 days prior to screening\n* Any evidence (histologic, cytogenetic, molecular, hematologic, or mixed) of relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening\n* Diagnosed with another malignancy (other than malignancy for which transplant was performed) within 3 years of study enrollment, unless previously treated with curative intent (e.g. complete resected basal or squamous cell carcinoma of the skin)\n* Active hepatitis B (defined as hepatitis B virus \\[HBV\\] surface antigen positive and HBV core antibody positive, with positive HBV deoxyribonucleic acid \\[DNA\\], or HBV positive core antibody alone with positive HBV DNA) or hepatitis C (defined as positive hepatitis C \\[HCV\\] antibody with positive HCV ribonucleic acid \\[RNA\\])\n* Suspected active or untreated\u002Finadequately treated latent tuberculosis (as confirmed by a positive QuantiFERON® test or other tuberculosis blood test if untreated)\n* History of clinically significant acute pancreatitis within 3 years prior to enrollment or evidence of chronic pancreatitis\n* History of myositis\n* Pregnant or breastfeeding\n* Previous exposure to colony stimulating factor 1 receptor (CSF-1R) therapies",{"count":73,"type":22},[53],"This phase II trial tests how well axatilimab works in treating patients with thickening or hardening (sclerosis) of the skin related to chronic graft-versus-host disease after a donor stem cell transplant. Chronic graft-versus-host disease (cGVHD) remains a major complication of donor stem cell transplants. Sclerosis, while not associated with a higher risk of death, can lead to serious disabilities. Usual treatments for cGVHD can be associated with significant side effects and unsatisfactory outcomes. A monoclonal antibody, like axatilimab, is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Axatilimab blocks a receptor and depletes cells that may be involved in the development of inflammation and fibrosis in cGVHD. Giving axatilimab may improve or prevent worsening of sclerosis related to cGVHD in patients after a donor stem cell transplant.",[56],{"date":261,"type":34},"2026-08-12",{"date":263,"type":34},"2025-08-06",{"date":265,"type":22},"2030-02-10",{"name":40,"class":41},{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":88},"100634078","dental-cleaning-to-prevent-chronic-graft-versus-host-disease-100634078","NCT07535008","Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* T-replete allogeneic hematopoietic cell transplantation for any indication. History of prior transplantation is allowed. Any conditioning regimen is allowed\n* One of the following HCT donor types:\n\n  * 9\u002F10 or 10\u002F10 human leukocyte antigen (HLA)-matched unrelated donor\n  * Cord blood\n* Willing to have an in-person 1-year long-term follow-up (LTFU) visit including an oral medicine at Fred Hutch (FH)\n* Ability to understand and sign a written informed consent document (or legal representative)\n\nExclusion Criteria:\n\n* Edentulous state\n* Bone marrow as graft source\n* Use of post-transplantation cyclophosphamide (PTCy) or ruxolitinib as GVHD prophylaxis\n* Use of anti-thymocyte globulin (ATG) in conditioning",{"count":274,"type":22},45,[25],"This clinical trial evaluates the feasibility and effectiveness of a post-transplant dental cleaning for the prevention of chronic graft versus host disease (GVHD) in patients undergoing an allogeneic hematopoietic cell transplant (HCT). HCT is the only curative treatment for some types of blood cancer. Unfortunately, this approach can lead to the development of GVHD, which is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Some research has shown that the bacteria that is present in the dental plaque soon after transplant may affect the development of chronic GVHD. Dental cleanings prior to transplant are part of the normal standard of care for patients undergoing HCT. Adding an additional cleaning shortly after HCT may be effective for preventing the development of chronic GVHD.",[56,278,29],"Acute Graft Versus Host Disease","2026-08-10",{"date":261,"type":34},{"date":282,"type":34},"2026-06-11",{"date":284,"type":22},"2029-04-30",{"name":40,"class":41},{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":23,"phases":295,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":298,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":299,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":88},"100630867","a-behavioral-application-for-improving-smoking-cessation-among-smokers-100630867","NCT07493252","A Behavioral Application for Improving Smoking Cessation Among Smokers","Actify! An mHealth Mood Management Tool to Improve Population-Level Smoking Cessation","Inclusion Criteria:\n\n* Age 18 or older\n* Currently smoke, averaging at least 5 cigarettes\u002Fday for the last 30 days\n* Interested in quitting smoking in the next 30 days\n* Experience downloading and using one or more apps on their smartphone\n* Either screens negative for depression (Patient Health Questionnaire - 9 item \\[PHQ-9\\] score 0-4; n = 906) or screens positive for mild to moderately severe current depressive symptoms (PHQ-9 score 5-19; n = 906)\n* Willing and able to complete all study activities and to receive compensation by mail\n* Comfortable reading and writing in English\n* Have a mobile data plan and\u002For access to WiFi to support the use of the assigned app\n* Reside in the United States (US)\n* Willing to provide information for an emergency contact in case of serious concerns about the participant's physical or mental health\n\nExclusion Criteria:\n\n* Self-report of currently receiving behavioral treatment for depression (e.g., psychotherapy or counseling, web- or app-based interventions); current use of pharmacotherapy for depression or for other mental health conditions that are not otherwise excluded is allowable (e.g., benzodiazepines, anticonvulsants, opioid agonists, antipsychotics)\n* Severe depression (PHQ-9 ≥ 20)\n* Current suicidal ideation reported on the PHQ-9\n* History of a suicide attempt\n* Self-reported lifetime diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, antisocial personality disorder, or borderline personality disorder; or self-reported lifetime diagnosis of an alcohol or drug use disorder with use of the substance(s) in the past 30 days\n* Currently receiving other smoking cessation treatments, including pharmacotherapies (nicotine replacement therapy, bupropion, or varenicline) and behavioral interventions (e.g. quitline counseling, other digital health programs), but excluding electronic (e)-cigarettes\u002Fvaping\n* Previous use of the QuitGuide program\n* Employees\u002Ffamily of investigator or study center\n* Member of the same household as another participant\n* Woman who is pregnant or breastfeeding, or planning to become pregnant\n* Having a Google voice number as their primary phone number (due to association with fraudulent study entry attempts in our previous work)\n* Currently incarcerated\n* Participated in earlier studies to develop the Actify! app",{"count":294,"type":22},1812,[25],"This clinical trial compares two smartphone applications, called Actify! (A \\& B) for improving smoking cessation outcomes in individuals who smoke. Actify! A is an app grounded in behavioral activation therapy, an evidence-based treatment for depression that can also be used to modify health behaviors such as smoking. The Actify! B app provides evidence-based tobacco cessation strategies based on current clinical guidelines.",[173],"NOT_YET_RECRUITING",{"date":261,"type":34},{"date":301,"type":22},"2026-11-01",{"date":303,"type":22},"2029-07-31",{"name":40,"class":41},{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":17,"sex":18,"minAge":312,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":23,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":319,"startDateStruct":320,"completionDateStruct":321,"leadSponsor":323,"locationsCount":88},"100630683","a-restorative-justice-based-lung-cancer-screening-decision-making-support-intervention-tailored-for-black-individuals-to-increase-lung-cancer-screening-among-black-community-members-restore-trial-100630683","NCT07490860","A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE Trial","Integrating Restorative Practices to Enhance Shared Decision-Making and Uptake of Lung Cancer Screening in Black Community Members (RESTORE)","Inclusion Criteria:\n\n* Identify as Black or African American\n* Between ages 50-77\n* Self-reported 20-pack year smoking history\n* Ongoing commercial tobacco use within the past 15 years\n* Proficiency in the English language\n\nExclusion Criteria:\n\n* Has a documented chest CT within the past one year\n* Personal history of lung cancer or symptoms associated with lung cancer","50 Years","77 Years",{"count":274,"type":22},[25],"This clinical trial develops and studies whether a restorative justice-based lung cancer screening (LCS) decision-making support intervention tailored for Black individuals increases LCS among Black community members. Lung cancer remains the leading cause of cancer deaths among Black men and women. LCS with yearly low-dose chest computed tomography (CT) is recommended for people with current or recent tobacco use (within 15 years) who are aged 50-80 with at least a 20 pack-year smoking history. LCS lowers lung cancer death by 20%; however, data shows that LCS completion remains low among minority groups in the United States. The restorative justice-based LCS decision-making support intervention in this trial has been specifically tailored to meet the needs of Black individuals. It is designed to reduce racial unfairness by promoting trust, shared understanding, and empowerment in clinical decision making while addressing the social and historical circumstances of health inequalities. This may be an effective way to increase LCS among Black community members.",[318],"Lung Carcinoma",{"date":261,"type":34},{"date":245,"type":22},{"date":322,"type":22},"2026-12-31",{"name":40,"class":41},{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":23,"phases":333,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":338,"startDateStruct":339,"completionDateStruct":340,"leadSponsor":342,"locationsCount":88},"100607932","phase-2-nemtabrutinib-and-lisocabtagene-maraleucel-for-the-treatment-of-relapsedrefractory-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-100607932","NCT07194980","Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed\u002FRefractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","Safety and Efficacy of the Addition of Nemtabrutinib to Lisocabtagene Maraleucel in Patients With Relapsed\u002FRefractory Chronic Lymphocytic Leukemia","Inclusion Criteria:\n\n* Confirmed diagnosis of CLL\u002FSLL per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) classification\n* Measurable disease by imaging (lymph node \\[LN\\] \\> 1.5cm) or absolute lymphocyte count (ALC) (\\> 5000\u002FμL) or marrow involvement of at least 30% by flow cytometry\n* Eligible for lisocabtagene maraleucel (liso-cel) as standard-of-care per Food and Drug Administration (FDA) label for CLL\u002FSLL\n* At least 18 years of age at time of study enrollment\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n* The ability to swallow and retain oral medication\n\n  * NOTE: Administration of nemtabrutinib is not permitted through a percutaneous endoscopic gastro-jejunal (J PEG) tube\n* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization\n\n  * Note: Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention. Hepatitis B screening tests should include HBsAg and anti-HBV. Hepatitis B screening tests are not required unless:\n\n    * Known history of HBV infection,\n    * As mandated by local health authority\n* Absolute neutrophil count (ANC) ≥ 500\u002FµL\n\n  * Growth factor and\u002For transfusion support is permissible to stabilize participant prior to study treatment if needed\n  * No lower limit if cytopenia is related to bone marrow involvement\n* Hemoglobin ≥ 8 g\u002FdL\n\n  * Growth factor and\u002For transfusion support is permissible to stabilize participant prior to study treatment if needed\n  * No lower limit if cytopenia is related to bone marrow involvement\n* Platelets ≥ 25 000\u002FµL\n\n  * Growth factor and\u002For transfusion support is permissible to stabilize participant prior to study treatment if needed\n  * No lower limit if cytopenia is related to bone marrow involvement\n* Creatinine ≤ 1.5 × upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate \\[GFR\\] can also be used in place of creatinine or CrCl) ≥ 30 mL\u002Fmin for participant with creatinine levels \\> 1.5 × institutional ULN\n\n  * Creatinine clearance (CrCl) should be calculated per institutional standard\n* Total bilirubin ≤ 1.5 × ULN OR direct bilirubin ≤ ULN for participants with total bilirubin levels \\> 1.5 × ULN\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase \\[SGPT\\]) ≤ 2.5 × ULN (≤ 5 × ULN for participants with liver metastases)\n* International normalized ratio (INR) OR prothrombin time (PT) ≤ 1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants\n* Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n* Cardiac (echocardiogram \\[Echo\\] or multi-gated acquisition scan \\[MUGA\\]) ejection fraction ≥ 40%\n\nExclusion Criteria:\n\n* Diagnosis of Richter Transformation\n* Clinically significant (symptomatic) central nervous system (CNS) involvement at time of study enrollment. Previously treated CNS disease is allowed if the participant is asymptomatic. Incidental findings including positive cerebral spinal fluid (CSF) studies are not exclusionary\n* Active infection and uncontrolled infection\n* Active HBV\u002Fhepatitis C virus (HCV) infection\n\n  * Participants must have completed curative anti-viral therapy for HCV at least 4 weeks prior to study enrollment\n  * Participants who are HBsAg positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to study enrollment\n  * Note: Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention\n* HIV with a detectable viral load or a CD4 count ≤ 350 cells\u002FµL at time of screening\n\n  * Participants with HIV who do not meet the above criteria are eligible if they are on a stable antiretroviral therapy (ART) regimen (ART must not be strong CYP3A4 inducers) for at least 4 weeks prior to study entry and are compliant with ART are eligible\n  * Patients with an AIDS defining opportunistic infection in the past 12 months prior to screening\n* Gastrointestinal dysfunction that may affect drug absorption (e.g., gastric bypass surgery, gastrectomy)\n* History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator\n* Corrected QT interval (QTc) prolongation (defined as a QTc \\> 450 msecs) or other significant electrocardiogram (ECG) abnormalities including second degree atrioventricular (AV) block type II, third degree AV block, or bradycardia (ventricular rate less than 50 beats\u002Fmin)\n* Known allergy\u002Fsensitivity to nemtabrutinib or any of the excipients\n* Known prior progressive disease while on nemtabrutinib\n\n  * NOTE: Refer to the investigator's brochure (IB) for details regarding prior recipients of nemtabrutinib\n* History of severe bleeding disorder defined as an ongoing congenital or acquired condition that leads to an increased likelihood of bleeding\n* History of a second malignancy\n\n  * NOTE: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder\n* A participant of childbearing potential (POCBP) who has a positive urine pregnancy test within 72 hours prior to study enrollment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n\n  * Note: In the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for participant to start receiving study medication\n* Need or anticipation of need for additional bridging therapy in addition to nemtabrutinib\n\n  * Palliative radiation therapy for less than 2 weeks or the use of prednisone 30mg (or the prednisone equivalent) for a maximum of 5 days is allowed and is not exclusionary\n* Currently being treated with the following drugs:\n\n  * P-gp substrates with a narrow therapeutic index\n  * CYP3A strong inducers\n  * CYP3A strong inhibitors\n  * NOTE: A washout period of at least 5 times the half-life after the last dose of any of the above treatments is required for a participant to be eligible for study enrollment\n* Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of inactivated vaccines are allowed\n* Is currently enrolled on another therapeutic clinical trial. Concurrent enrollment on another therapeutic clinical trial or any trial designed to impact the efficacy of anti-cancer therapy is prohibited\n* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration\n* Has not adequately recovered after 4 weeks from major surgery or has ongoing surgical complications\n\n  * Note: Biopsy and placement of central venous access devices are not considered major surgery\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n* Any condition or history that the study investigator deems not in the best interest of the patient to participate",{"count":332,"type":22},20,[53],"This phase II trial studies how well the addition of nemtabrutinib to lisocabtagene maraleucel in treating patients with chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma (CLL\u002FSLL) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Nemtabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lisocabtagene maraleucel is a type of treatment called chimeric antigen receptor (CAR) T-cell therapy, in which a patient's T-cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T-cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T-cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T-cells are grown in the laboratory and given to the patient by infusion for treatment. Adding nemtabrutinib to lisocabtagene maraleucel may be an effective treatment for relapsed\u002Frefractory CLL\u002FSLL.",[336,337],"Recurrent Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","Refractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma",{"date":261,"type":34},{"date":245,"type":22},{"date":341,"type":22},"2029-10-20",{"name":40,"class":41},{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":23,"phases":351,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":356,"startDateStruct":357,"completionDateStruct":358,"leadSponsor":360,"locationsCount":88},"100600227","randomization-for-the-identification-of-best-treatment-intensity-for-less-fit-adults-with-acute-myeloid-leukemia-and-myeloid-neoplasms-100600227","NCT07094750","Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms","Impact of Treatment Intensity on Survival, Quality of Life, and Resource Utilization in Medically Less Fit Adults With Acute Myeloid Leukemia or High-Grade Myeloid Neoplasms: A Randomized Pilot Study","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of high grade myeloid neoplasm (\\> 10% blasts in blood or marrow), other than acute promyelocytic leukemia (APL) according to the 2022 International Consensus Classification (ICC) classification. Patients with acute leukemias of ambiguous lineage are eligible\n* The use of cytoreductive therapy before treatment is permitted. Patients with symptoms\u002Fsigns of leukostasis, white blood cell (WBC) \\> 100,000\u002FμL, or acute symptoms that in the opinion of the treating physician are likely related to their high-grade myeloid neoplasm may receive up to 2 doses of cytarabine (up to 500 mg\u002Fm\\^2 each) prior to study day 1\n* Patients may have received treatment for antecedent low-grade myeloid neoplasm (\\\u003C 10% myeloid blasts on blood or bone marrow)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3 (for patients aged \\\u003C 75 years) or ECOG performance status of 0 - 2 (for patients aged ≥ 75 years)\n* The presence of one or more of the following criteria for 'unfitness'. (Patients without respiratory symptoms at rest are eligible and should only complete spirometry\u002Fdiffusion capacity of the lung for carbon monoxide \\[DLCO\\] measurements as clinically indicated):\n\n  * ECOG Performance Status of 2 or 3\n  * Cardiac history of congestive heart failure (CHF) requiring treatment or ejection fraction ≤ 50% or chronic stable angina\n  * Documented DLCO ≤ 65% or forced expiratory volume in 1 second (FEV1) ≤ 65%; or dyspnea at rest, or requiring supplemental oxygen\n  * Creatinine clearance ≥ 30 mL\u002Fmin to \\\u003C 45 ml\u002Fmin\n  * Moderate hepatic impairment with total bilirubin \\> 1.5 to ≤ 3.0 × upper limit of normal (ULN)\n  * Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy\n* Adequate cardiac function:\n\n  * Patients aged ≤ 60 years without a history of cardiac disease or evidence of heart failure are eligible if they also exhibit the following:\n\n    * Chest x-ray (CXR) without evidence of moderate or severe pulmonary edema or pleural effusion, and a normal cardio-mediastinal silhouette\n    * Electrocardiogram (ECG) without evidence of atrial or ventricular chamber enlargement\n    * Note that patients with either abnormal CXR or ECG should have a structural heart assessment (echocardiogram, multigated acquisition scan \\[MUGA\\] or similar) and are eligible if left ventricular ejection fraction (LVEF) \\> 40% and the abnormalities in the CXR\u002FECG do not preclude safe administration of intensive chemotherapy\n  * Patients with a documented left ventricular ejection fraction (LVEF) ≥ 40%, assessed within 3 months prior to registration, e.g. by MUGA scan or echocardiography, or another appropriate diagnostic modality are eligible\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3x ULN, unless judged due to leukemic organ involvement\n* Total bilirubin ≤ 3 x ULN unless judged due to leukemic organ involvement, Gilbert's syndrome, or hemolysis\n* Women of childbearing potential and men must agree to use adequate contraception for an appropriate period of time during and after the completion of study treatment\n* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* Ability to understand and the willingness to provide informed consent\n\nExclusion Criteria:\n\n* Known hypersensitivity to cytarabine, anthracycline, hypomethylating agents, or venetoclax\n* Cardiovascular disability status of New York Heart Association class ≥ 2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in fatigue, palpitations, dyspnea, or anginal pain\n* Subject has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, or any other medical condition that in the opinion of the investigator would adversely affect his\u002Fher participating in this study\n* Subject exhibits evidence of other clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial or fungal)\n* Concomitant illness associated with a likely survival of \\\u003C 1 year\n* Active pregnancy or breast feeding",{"count":73,"type":22},[25],"This clinical trial studies whether less fit adults with acute myeloid leukemia (AML) or myeloid neoplasms are willing to let a computer program decide (randomization) whether they receive lower- or higher-intensity chemotherapy. Historically, treatment decision-making for patients with AML or myeloid neoplasms has divided patients into two categories, with patients considered fit receiving intensive \"curative\" chemotherapy, and patients considered unfit, such as older patients with a higher risk of early death from therapy, receiving non-intensive \"palliative\" therapy or no therapy. With the introduction of new treatment agents, it has become difficult to determine the difference between intensive and non-intensive therapy, especially for patients considered unfit for whom treatment-related side effects remain a concern. Treatment intensity is best identified through randomized trials but often patients are unwilling to undergo randomization due to preset beliefs. However, with improved supportive care and the awareness that new treatment agents may have similar risks as intensive therapy, it may be possible that more patients are willing to be randomized. This may help identify the best treatment intensity for less fit adults with AML or myeloid neoplasms, which may improve outcomes.",[354,241,355],"Acute Leukemia of Ambiguous Lineage","Myeloid Neoplasm",{"date":261,"type":34},{"date":245,"type":22},{"date":359,"type":22},"2029-06-08",{"name":40,"class":41},{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":23,"phases":369,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":298,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":375,"leadSponsor":377,"locationsCount":110},"100575396","a-pilot-unrestricted-payment-program-for-early-stage-cancer-patients-the-payment-trial-100575396","NCT06771739","A Pilot Unrestricted Payment Program for Early-stage Cancer Patients: the PAYMENT Trial","Preventing Financial Adversity Among Early-Stage Cancer Patients Through Unrestricted Cash (PAYMENT) Pilot Study","Inclusion Criteria:\n\n* Age \\>= 18\n* Ability to understand English\n* Ability to understand and willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants\n* Within 90 days of a non-metastatic or early-stage solid tumor receiving or rescheduled to receive treatment in the neoadjuvant, adjuvant or definitive setting for curative intent. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2\n* Current cancer patient at PeaceHealth (Southwest Medical Center or St. Joes)\n* Not current Medicaid enrollee\n* Not enrolled in hospice\n* Screens positive for financial fragility",{"count":332,"type":22},[25],"This clinical trial studies whether an unrestricted cash payment program can be used to improve financial and clinical outcomes in early-stage cancer patients with financial concerns. A cancer diagnosis can have poor financial outcomes, and the cost of cancer treatment can lead to high medical debt and financial hardships for the patient and family. Financial hardship during cancer treatment is associated with adverse outcomes including poorer quality of life, lower treatment compliance, more aggressive use of hospital-based care, and worse survival. Newly diagnosed cancer patients with financial concerns may avoid treatment entirely so that they can continue to work and maintain income, provide for their families, or pay rent. An unrestricted cash payment program provides patients with a preloaded cash card once monthly. The patients can choose what to use the card to pay for and may include items like food, rent, or utilities. This provides a period of guaranteed income for the patients and may prevent them from falling into poverty and improve financial and clinical outcomes.",[372],"Malignant Solid Neoplasm",{"date":261,"type":34},{"date":245,"type":22},{"date":376,"type":22},"2026-12-01",{"name":40,"class":41},{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":385,"minAge":19,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":23,"phases":388,"briefSummary":389,"conditions":390,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":88},"100534231","phase-1-cell-therapy-steap1-cart-with-enzalutamide-for-the-treatment-of-patients-with-metastatic-castration-resistant-prostate-cancer-100534231","NCT06236139","Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer","Phase 1\u002F2 Dose-Escalation and Cohort Study of STEAP1 CART With Enzalutamide in Participants With mCRPC","Inclusion Criteria:\n\n* Tissue confirmation of prostate adenocarcinoma\n* Measurable disease by RECIST 1.1 criteria or bone only metastases with measurable PSA ( ≥ 1 ng\u002FmL)\n* Must have progressed (at least 2 rising PSA levels with at least a 1-week interval and a minimum PSA of 1.0 ng\u002FmL, progression per RECIST 1.1, or 2 or more new bone lesions by bone scan), after becoming castration-resistant\n* Have received the following for metastatic prostate cancer:\n\n  * At least two lines of treatment\n  * At least two Food and Drug Administration (FDA)-approved therapies with at least one being a second generation androgen receptor signaling inhibitor (e.g., abiraterone, darolutamide, apalutamide, or enzalutamide)\n  * All available targeted therapies for which they are eligible in the metastatic setting (e.g., PARP inhibitors for BRCA 1\u002F2 and immune checkpoint inhibitor for MSI-H or TMB-H ≥ 10 mut\u002FMb)\n* Castrate levels of testosterone (\\\u003C 50 ng\u002FdL) with or without the use of androgen deprivation therapy (ADT)\n* 18 years or older at the time of enrollment\n* Capable of understanding and providing a written informed consent\n* Fertile male participants and their female partners must be willing to use an effective contraceptive method before, during, and for at least 4 months after the STEAP1 CART cell infusion\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Participants will be permitted to receive radiation therapy for palliative purposes throughout the study period, except during the 2-week period prior to undergoing leukapheresis\n* Serum creatinine =\\\u003C 1.5 x upper limit of normal (ULN) or estimated creatinine clearance \\> 50 mL\u002Fmin as calculated using the Cockcroft-Gault formula and not dialysis dependent\n* Total bilirubin ≤ 1.5 x ULN. Participants with suspected Gilbert syndrome may be included if Total bilirubin (Bili) \\> 3 mg\u002FdL but no other evidence of hepatic dysfunction\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C 5 x ULN\n* ≤ grade 1 dyspnea and oxygen saturation (SaO2) ≥ 92% on ambient air\n* If pulmonary function tests (PFTs) are performed based on the clinical judgement of the treating physician, participants with forced expiratory volume in 1 second (FEVI) \\>= 50% of predicted and diffusion capacity of the lung for carbon monoxide (DLCO) (corrected) of \\>= 40% of predicted will be eligible\n* Participants \\>= 60 years of age are required to have left ventricular ejection fraction (LVEF) evaluation performed within 1 year prior to lymphodepletion chemotherapy. LVEF may be established with echocardiogram or MUGA scan, and left ejection fraction must be \\>= 35%. Cardiac evaluation for other participants is at the discretion of the treating physician\n* Absolute neutrophil count (ANC) \\> 1500 cells\u002F mm\\^3\n* Hemoglobin \\>= 9 g\u002FdL\n* Platelets \\> 100,000 per mm\\^3\n\nExclusion Criteria:\n\n* Expecting to conceive or father children for the duration of the trial through 4 months after T cell infusion\n* Active autoimmune disease: Participants with active autoimmune disease requiring immunosuppressive therapy are excluded. Case by case exemptions are possible with approval by principal investigator (PI)\n* Corticosteroid therapy at a dose equivalent of \\>15 mg of prednisone per day (or equivalent). Pulsed corticosteroid use for disease control is acceptable\n* Concurrent use of other investigational anti-cancer agents except for ADT\n* Active uncontrolled infection: human immunodeficiency virus (HIV) positive participants on highly active antiretroviral therapy (HAART) with a CD4 count \\> 500 cells\u002Fmm\\^3 are considered controlled, as are individuals with a history of hepatitis C who have successfully completed antiviral therapy with an undetectable viral load, and those with hepatitis B who have hepatitis well controlled on medication\n* Uncontrolled concurrent illness: Participants may not have uncontrolled or concurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia that would limit compliance with study requirements\n* Participants with brain metastasis\n* Active treatment for prior immune related adverse event to any immunotherapy: Participants receiving ongoing treatment for prior serious immune-related adverse events are excluded, with exception of hormone supplementation or corticosteroid therapy at equivalent of \\> 15 mg prednisone (or equivalent) per day, unless otherwise approved by PI\n* Significant underlying neurologic disease: Study participants must not have significant active underlying neurologic disease, unless approved by PI. Peripheral neuropathy related to diabetes or prior chemotherapy is acceptable\n* Other medical, social, or psychiatric factor that interferes with medical appropriateness and\u002For ability to comply with study, as determined by the PI\n* Known allergic reactions to any of the components of study treatments\n* Participants with no bridging therapy options according to the treating medical oncologist. The specific bridging treatment plan must be documented in the Electronic Medical Record (EMR) by the treating medical oncologist within 2 weeks of signing informed consent","MALE",{"count":387,"type":22},48,[238,53],"This phase I\u002FII trial tests the safety and effectiveness of cell therapy (STEAP1 CART) with enzalutamide in treating patients with prostate cancer that continues to grow despite surgical or medical treatments to block androgen production (castration-resistant) and that has spread from where it first started (the prostate) to other places in the body (metastatic). Prostate cancer is the second leading cause of cancer deaths in men. Localized prostate cancer is often curable and even metastatic disease may respond to treatment for a few years. Despite multiple therapies, including hormone therapy and chemotherapy, metastatic castration-resistant prostate cancer (mCRPC) remains an incurable disease. Recently, adoptive cellular immunotherapies have been developed to transfer immunogenic cells to the patient to produce an anti-tumor response. Chimeric antigen receptor T (CART)-cell therapy is a type of treatment in which a patient's T-cells (a type of immune cell) are changed in the laboratory so they will attack tumor cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's tumor cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Prostate stem cell antigen and prostate specific membrane antigen CAR T cell therapies have been shown to be safe and effective, but objective tumor responses remain rare. STEAP1 is an antigen that promotes cancer growth and spread and is found to be broadly expressed in mCRPC tissues. STEAP1 CART is CAR T cells that have been engineered with a STEAP1 antigen to better target prostate tumor cells. Enzalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of cancer cells. Giving STEAP1 CART with enzalutamide may kill more tumor cells in patients with mCRPC.",[391,392,393],"Metastatic Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8","2026-08-07",{"date":242,"type":34},{"date":397,"type":34},"2024-11-26",{"date":399,"type":22},"2027-03-30",{"name":40,"class":41},{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":407,"minAge":19,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":120,"phases":4,"briefSummary":410,"conditions":411,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":88},"100649090","influencing-next-generation-oncologic-outcomes-through-rapid-integration-of-functional-precision-medicine-noori-a-feasibility-study-of-smartmatch-in-rare-gynecologic-cancers-100649090","NCT07731880","Influencing Next-Generation Oncologic Outcomes Through Rapid Integration of Functional Precision Medicine (NOORI): A Feasibility Study of SmartMatch in Rare Gynecologic Cancers","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologically confirmed rare gynecologic malignancy, including but not limited to those listed\n* Metastatic or unresectable disease, OR disease for which additional systemic therapy is indicated\n* Fresh tumor tissue available from a SOC surgical procedure or biopsy that in the judgment of the treating team will yield adequate viable tumor for SmartMatch analysis\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Adequate organ function to receive systemic therapy as determined by the treating oncologist (protocol does not specify thresholds because therapy is not mandated)\n* Ability to understand and willingness to sign informed consent\n* Willingness to allow data abstraction from the electronic health record for study endpoints\n\nExclusion Criteria:\n\n* Lack of tumor tissue suitable for SmartMatch analysis\n* Purely borderline tumors or benign ovarian\u002Futerine neoplasms\n* Any condition that, in the opinion of the treating oncologist or PI, would interfere with receiving systemic therapy\n* Inability to provide informed consent or comply with study procedures","FEMALE",{"count":409,"type":22},30,"This study is being done to determine how easy it is to use standard of care (SOC) surgical resections or biopsy for SmartMatch analysis to determine treatment options in advanced gynecological malignancies.",[412,413,414],"Malignant Female Reproductive System Neoplasm","Metastatic Malignant Female Reproductive System Neoplasm","Unresectable Malignant Female Reproductive System Neoplasm","2026-08-05",{"date":417,"type":34},"2026-08-06",{"date":419,"type":22},"2026-09",{"date":421,"type":22},"2029-07",{"name":40,"class":41},{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":23,"phases":432,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":437,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":42},"100578945","phase-2-remdesivir-for-the-treatment-of-upper-respiratory-tract-infection-due-to-rsv-in-immunocompromised-individuals-100578945","NCT06817889","Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals","An Open-Label Study to Assess the Safety and Efficacy of Remdesivir for Treatment of Symptomatic Laboratory-Confirmed Respiratory Syncytial Virus Infection of the Upper Respiratory Tract in Patients Receiving Cellular or Bispecific Antibody Therapies","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* Willing and able to provide written informed consent, or with a legal representative who can provide informed consent (where locally approved)\n* RSV confirmed by local lab testing via nucleic acid amplification test (e.g. polymerase chain reaction \\[PCR\\] or respiratory viral panel \\[RVP\\]) using an upper respiratory tract sample collected within the 5 days prior to day 1 (RDV dosing)\n* Symptomatic RSV infection of the upper respiratory tract, with symptom onset and positive microbiologic testing within the 5 days prior to day 1 (RDV dosing). Symptomatic RSV infection is defined as having new upper respiratory symptom(s) or worsening of a pre-existing upper respiratory symptom (if chronic and associated with a previously existing diagnosis, such as chronic lung disease, chronic rhinorrhea, or seasonal allergies)\n* Receiving treatment for a refractory or relapsed hematologic malignancy, or received a hematopoietic cell transplant (HCT), chimeric antigen receptor T cell therapy (CARTx), or bispecific antibody (bsAb) therapy within the past 365 days (relative to RSV diagnosis date)\n* Categorized as moderate-risk (overall score 3-6) or high-risk (overall score 7-10) per an adapted version of the Immunodeficiency Scoring Index (ISI) for RSV, as below, relative to the day of RSV diagnosis:\n\n  * 1 point:\n\n    * Recent (within the prior 30 days) allogeneic HCT, autologous HCT, or CARTx\n    * Corticosteroids within the prior 30 days for management of graft versus host disease (GVHD) or cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).\n  * 2 points:\n\n    * Age ≥ 40 years\n  * 3 points:\n\n    * Absolute neutrophil count (ANC) \\\u003C 500 cells\u002FμL within the prior 7 days\n    * Absolute lymphocyte count (ALC) \\\u003C 200 cells\u002FµL within the prior 7 days\n* Oxygen saturation (SpO2) 93% or greater on room air and at rest (to be measured after participant has rested in a quiet room for ≥ 2 minutes, with oxygen \\[O2\\] saturation probe on finger or earlobe for ≥ 1 minute, with saturation reading remaining ≥ 93%) at screening\n* Willingness to take study drug and complete necessary study procedures\n* Participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception as described\n\nExclusion Criteria:\n\n* Received or receiving an approved or authorized direct-acting antiviral therapy with potential efficacy against RSV (e.g. ribavirin) for ≥ 24 hours within the prior 7 days, and\u002For expected to receive anti-RSV direct-acting antiviral therapies for RSV during the course of the study at the time of screening\n* Received or receiving investigational direct-acting antiviral therapies against RSV for the current RSV episode\n* Received any investigational anti-RSV monoclonal antibodies or off-label use of approved anti-RSV monoclonal antibodies within \\\u003C 4 months or \\\u003C 5 half-lives, whichever is longer, before screening, or expected to receive anti-RSV monoclonal antibodies during the course of the study at the time of screening\n* Received an RSV vaccine after cellular therapy or after starting the current antitumor therapeutic regimen\n* Participation in any other concurrent clinical trial of an experimental treatment for RSV, including RSV vaccines\n* Alanine aminotransferase (ALT) ≥ 5 times the upper limit of normal within 7 days prior to screening\n* Unable to tolerate nasal sampling required for this study, as determined by the investigator (e.g., history of significant epistaxis, nasopharyngeal anatomical abnormalities, nasal or sinus surgery)\n* A life expectancy of three months or less, as determined by the investigator\n* Pregnant, as determined by a Point-of-Care urine pregnancy test or reported by the patient or their electronic health record within 7 days of screening\n* Receiving, requiring, or expected to require supplemental oxygen for RSV-related illness or SpO2 \\\u003C 93% at rest \\\u003C 24 hours prior to study drug administration\n* Previous infection or treatment for RSV, or previous treatment or hospitalization for another respiratory viral infection, \\\u003C 28 days before screening\n* Documented positive test for other respiratory viruses concomitantly (limited to influenza, parainfluenza, adenovirus, human metapneumovirus, or coronavirus \\[including SARS-CoV-2\\]) ≤ 7 days prior to screening, as determined by local testing (additional testing not required)\n* Clinically significant bacteremia or fungemia ≤ 7 days prior to screening and not adequately treated, as determined by the investigator\n* Clinically significant bacterial, fungal, or viral pneumonia within two (2) weeks prior to screening and not adequately treated, as determined by the investigator\n* Clinically significant symptoms of CRS or ICANS within the prior 72 hours before screening that is not adequately controlled, as determined by the investigator\n* Any inability to take study drug or comply with study procedures that, in the opinion of the investigator, would make the participant unsuitable for the study\n* Known hypersensitivity or allergy to the study drug, its metabolites, or formulation excipients",{"count":431,"type":22},60,[53],"This phase II trial tests how well remdesivir works for treatment of respiratory syncytial virus (RSV) infection of the upper respiratory tract in patients receiving cellular or bispecific antibody therapy. Cellular or bispecific antibody therapies cause suppression of the immune system, making infections more frequent and reducing the body's ability to fight the infections. RSV infections are one of the most common respiratory infections in immunocompromised individuals and can cause significant pneumonia and even death. Remdesivir is in a class of medications called antivirals. It works by stopping viruses from spreading in the body.",[29,435,436],"Autoimmune Disease","Respiratory Syncytial Virus Infection",{"date":417,"type":34},{"date":439,"type":34},"2025-12-23",{"date":441,"type":22},"2027-11-30",{"name":40,"class":41},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":450,"enrollmentInfo":451,"targetDuration":4,"studyType":23,"phases":453,"briefSummary":454,"conditions":455,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":88},"100562958","phase-1-fh-folr1-chimeric-antigen-receptor-t-cell-therapy-for-treating-pediatric-patients-with-relapsed-or-refractory-acute-myeloid-leukemia-100562958","NCT06609928","FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia","A Phase 1 Study of FOLR1 CAR T for Pediatric Patients With FOLR1\u002FCBFA2T3::GLIS2+ Relapsed or Refractory AML","Inclusion Criteria:\n\n* Subject age ≤ 6 years.\n* Weight ≥ 7 kilograms.\n* AML that expresses FOLR1 by flow cytometry as assessed by Hematologics, Inc.\n\nLaboratory and meets one of the below definitions:\n\n* For subjects who have previously received an allogeneic hematopoietic cell transplantation (HCT), any evidence of AML re-emergence post HCT detectable by flow cytometry.\n* First relapse of AML ≤ 6 months from initial diagnosis.\n* First relapse of AML \\> 6 months from initial diagnosis with minimal residual disease (MRD) ≥ 0.05% by flow cytometry after at least one re-induction attempt (one cycle of therapy).\n* Second or greater relapse of AML.\n* Refractory AML, defined as ≥ 0.1% leukemic cells determined by flow cytometry or \\> 1% on biopsy after 2 cycles of chemotherapy.\n\n  * Able to tolerate apheresis.\n  * Life expectancy ≥ 8 weeks.\n  * Has an appropriate stem cell donor source identified.\n  * Lansky performance status score of ≥ 50. Subjects who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for purposes of assessing performance status.\n  * The subject must discontinue all anticancer agents and radiotherapy and, in the opinion of the investigator, have fully recovered from significant acute toxic effects of all prior chemotherapy, immunotherapy, and radiotherapy:\n* Chemotherapy and biologic agents: All chemotherapy and biologic therapy not specifically mentioned below must be discontinued ≥ 14 days prior to enrollment, with the exception of intrathecal chemotherapy for which there is not a required washout period.\n* Steroid use: All corticosteroid therapy (unless physiologic replacement dosing) must be discontinued ≥ 7 days prior to enrollment, unless being used to treat graft-versus-host disease (GVHD) (if being used to treat GVHD see requirements).\n* Tyrosine kinase inhibitor (TKI) use: All TKIs must be discontinued ≥ 3 days prior to enrollment.\n* Hydroxyurea: must be discontinued ≥ 1 day prior to enrollment.\n* FOLR1 targeting therapy must be discontinued within 30 days prior to enrollment.\n\n  * Gene modified cellular therapy:\n* Must be at least 30 days from most recent gene modified cell therapy infusion and document no evidence of modified cells in the peripheral blood OR\n* Must be at least 60 days from most recent gene modified cell therapy.\n\n  * Serum creatinine ≤ 1.5 x the upper limit of normal (ULN) based on the following:\n* Age 1 to \\\u003C 2 years: maximum serum creatinine 0.6 mg\u002FdL for male and 0.6 mg\u002FdL for female.\n* Age 2 to \\\u003C 6 years: maximum serum creatinine 0.8 mg\u002FdL for male and 0.8 mg\u002FdL for female.\n* Age 6 to \\\u003C 10 years: maximum serum creatinine 1 mg\u002FdL for male and 1 mg\u002FdL for female.\n\n  * Total bilirubin ≤ 3 times ULN for age OR conjugated bilirubin ≤ 2 mg\u002FdL.\n  * Alanine aminotransferase (ALT)(serum glutamic-pyruvic transaminase \\[SGPT\\]) ≤ 5 times ULN.\n  * Shortening fraction ≥ 28% OR ejection fraction (EF) ≥ 50% as measured by echocardiogram.\n  * Oxygen saturation ≥ 92% on room air without supplemental oxygen or mechanical ventilation.\n  * Absolute lymphocyte count (ALC) ≥ 100 cells\u002FuL.\n  * Virology testing negative within 3 months prior to enrollment, to include:\n* HIV antigen \\& antibody.\n* Hepatitis B surface antigen.\n* Hepatitis C antibody OR if positive, hepatitis C polymerase chain reaction (PCR) is negative.\n\n  * Subject and\u002For legally authorized representative has signed the informed consent form for this study.\n\nExclusion Criteria:\n\n* Active malignancy other than acute myeloid leukemia.\n* History of symptomatic non-AML central nervous system (CNS) disease or ongoing symptomatic CNS disease requiring medical intervention, including paresis, aphasia, cerebrovascular ischemia\u002Fhemorrhage, severe brain injury, dementia, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder (subjects with non-febrile seizure disorder controlled on anti-epileptic medication and without seizure activity within 1 month are eligible).\n* CNS AML involvement that is symptomatic and in the opinion of the investigator, cannot be controlled during the interval between enrollment and T cell infusion.\n* If history of allogeneic stem cell transplant: active GVHD or receiving immunosuppressive therapy for treatment or prevention of GVHD within 4 weeks prior to enrollment.\n* If history of allogeneic stem cell transplant and patient has received donor lymphocyte infusion (DLI) the subject is \\\u003C 8 weeks from DLI infusion.\n* Presence of active severe infection, defined as:\n\n  * Positive blood culture within 48 hours of enrollment, OR\n  * Fever above 38.2 degrees Celsius (C), AND clinical signs of infection within 48 hours of enrollment.\n* Primary immunodeficiency syndrome.\n* Subject has received prior virotherapy.\n* Subject and\u002For legally authorized representative unwilling to provide consent\u002Fassent for participation in the 15-year follow-up period, required if FH-FOLR1 CAR T cell therapy is administered.\n* Presence of any condition that, in the opinion of the investigator, would prohibit the subject from undergoing treatment under this protocol.\n* Considered by the investigator to be unable to tolerate a lymphodepleting regimen.","6 Years",{"count":452,"type":22},12,[238],"This phase I trial tests the safety, side effects, and best dose of FH-FOLR1 chimeric antigen receptor (CAR) T cells in treating pediatric patients with FOLR1+ acute myeloid leukemia (AML) that has come back after a period of improvement (recurrent) or has not responded to previous treatment (refractory). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a FOLR1 on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Chemotherapy drugs, such as fludarabine and cyclophosphamide, are given to a patient before the manufactured FH-FOLR1 CAR T cells are infused back into the patient to assist in the CAR T cell activity in the patient. The trial is evaluating if giving FH-FOLR1 CAR T cell therapy is safe and tolerable for pediatric patients with recurrent or refractory AML.",[456,457],"Recurrent Childhood Acute Myeloid Leukemia","Refractory Childhood Acute Myeloid Leukemia","2026-08-04",{"date":417,"type":34},{"date":461,"type":34},"2025-02-24",{"date":463,"type":22},"2042-10-01",{"name":40,"class":41},{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":385,"minAge":4,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":23,"phases":474,"briefSummary":475,"conditions":476,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":478,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":88},"100527274","phase-2-vorinostat-and-177lu-psma-617-for-the-treatment-of-psma-low-metastatic-castration-resistant-prostate-cancer-100527274","NCT06145633","Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer","Vorinostat to Augment Response to 177Lutetium-PSMA-617 in the Treatment of Patients With PSMA-Low Metastatic Castration-Resistant Prostate Cancer","Inclusion Criteria:\n\n* Documented histologically confirmed adenocarcinoma of the prostate.\n* Patient must have evidence of castration resistant prostate cancer as evidenced by PSA progression (per Prostate Cancer Working Group 3 \\[PCWG3\\] criteria) and a castrate serum testosterone level (i.e., ≤ 50 mg\u002FdL).\n* PSMA SUVmean \\\u003C 10 as determined by 68Ga-PSMA-11 PET.\n* Patients must have received a next-generation androgen receptor-signaling inhibitor (e.g. abiraterone, enzalutamide, apalutamide, darolutamide). There must be at least a 2-week washout period after stopping these agents. Patients should be weaned off steroids at least 1 week prior to starting treatment.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* At least one lesion (measurable and\u002For non-measurable) that can be accurately assessed at baseline by CT and\u002For bone scan and is suitable for repeated assessment.\n* Hemoglobin ≥ 10 g\u002FdL (measured within 28 days prior to administration of study treatment)\n* Absolute neutrophil count (ANC) ≥ 1.5 x 10\\^9\u002FL (measured within 28 days prior to administration of study treatment)\n* Platelet count ≥ 100 x 10\\^9\u002FL (measured within 28 days prior to administration of study treatment)\n* Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (measured within 28 days prior to administration of study treatment)\n* Aspartate aminotransferase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN, unless liver metastases are present in which case they must be ≤ 5 x ULN (measured within 28 days prior to administration of study treatment) . For patients with known Gilbert's Syndrome they must be ≤ 3 x ULN (measured within 28 days prior to administration of study treatment)\n* Calculated creatinine clearance ≥ 50 mL\u002Fmin (using Cockcroft-Gault formula) (measured within 28 days prior to administration of study treatment)\n* Patients and their partners, who are sexually active and of childbearing potential must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for 3 months after last dose of study drug to prevent pregnancy in a partner.\n* Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.\n\nExclusion Criteria:\n\n* Evidence of serious and\u002For unstable pre-existing medical, psychiatric or other condition that could interfere with patient safety or provision of informed consent to participate in this study.\n* Evidence of metastatic neuroendocrine\u002Fsmall cell prostate cancer (NEPC). Note: baseline biopsy is not required but is strongly encouraged if a patient is found to have an FDG-positive\u002FPSMA-negative lesion on baseline imaging.\n* Patients receiving any systemic therapy (aside from an luteinizing hormone-releasing hormone \\[LHRH\\] analogue) or radiotherapy within 2 weeks prior to study treatment.\n* Any previous treatment with an HDAC inhibitor (including valproic acid) or 177Lu-PSMA-617.\n* Persistent toxicities (CTCAE grade \\>2) from prior cancer therapy, excluding alopecia and stable neuropathy.\n* Patients considered a poor medical risk due to a serious, uncontrolled medical disorder or active, uncontrolled infection. Examples include, but are not limited to uncontrolled seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.\n* Patients who are known to be serologically positive for human immunodeficiency virus (HIV) and a CD4 count \\\u003C 200.\n* Patients with known active hepatitis (i.e. Hepatitis B or C). Prior Hep C infection is allowed as long as polymerase chain reaction (PCR) is negative.\n* Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.\n* Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.\n* Deep vein thrombosis or pulmonary embolism diagnosed within the past six months.\n* Active use of coumarin-derived anticoagulant medication (i.e. warfarin).\n* Serious cardiac disorder, including but not limited to uncontrolled ventricular arrhythmia, recent (within 12 months) myocardial infarction, resting electrocardiogram (ECG) indicating Fridericia's corrected QT interval prolongation \\> 500ms, or congenital long QT syndrome.",{"count":473,"type":22},15,[53],"This phase II trial tests how well vorinostat works in treating patients with prostate-specific membrane antigen (PSMA)-low castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) (mCRPC). Prostate cancer that has not spread to other parts of the body (localized) is typically treated through surgery or radiotherapy, which for many men is curable. Despite definitive local therapy, cancer that has come back after a period of improvement (recurrent) disease develops in 27-53% of men. Often this is detected by measurement of prostate-specific antigen (PSA) without visible evidence of metastatic disease. Lutetium Lu 177 vipivotide tetraxetan (177Lu-prostate specific membrane antigen \\[PSMA\\]-617) is a new small molecule PSMA-targeted radioactive therapy that has been approved by the Food and Drug Administration for the treatment of adult patients with PSMA-positive mCRPC who have been treated with androgen receptor inhibitors and taxane-based chemotherapy. Vorinostat is used to treat various types of cancer that does not get better, gets worse, or comes back during or after treatment with other drugs. Vorinostat is a drug which inhibits the enzyme histone deacetylase and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vorinostat and 177Lu-PSMA-617 may kill more tumor cells in in patients with PSMA-low mCRPC.",[477,392,393],"Castration-Resistant Prostate Carcinoma",{"date":417,"type":34},{"date":480,"type":34},"2024-09-18",{"date":482,"type":22},"2027-12-30",{"name":40,"class":41},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":407,"minAge":19,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":23,"phases":493,"briefSummary":494,"conditions":495,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":499,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":88},"100506431","online-nutrition-education-to-decrease-the-side-effects-of-chemotherapy-in-patients-with-breast-cancer-100506431","NCT05874297","Online Nutrition Education to Decrease the Side Effects of Chemotherapy in Patients With Breast Cancer","Feasibility and Pilot Study Testing an Online Digital Intervention to Improve Symptom Management During Breast Cancer Chemotherapy","ONE","Inclusion Criteria:\n\n* 18 years of age or older.\n* Stage I-III breast cancer.\n* Current breast cancer patients scheduled to receive ddAC-T(+\u002F-C), TCHP, or TCPembro-AC chemotherapy at Fred Hutch South Lake Union (can enroll prior to receipt of 2nd cycle).\n* Not pregnant and no plan to become pregnant during chemotherapy treatment.\n* Ability to speak and read English.\n* Access to smartphone, tablet, or computer and Internet.\n* Willing and able to complete all study activities through the end of chemotherapy, including completing online questionnaires and telephone assessments.\n* Women must not be pregnant at time of enrollment based on self-report.\n* Able to understand and willing to sign written informed electronic (e) consent in English.",{"count":73,"type":22},[25],"This trial tests an online nutrition education program focused on decreasing nutrition-related side effects of chemotherapy in patients with breast cancer. Patients undergoing chemotherapy are at risk for complications such as diarrhea or constipation which can lead to poor nutritional intake and malabsorption of nutrients. This study is testing the effects of information delivered via the Cook for Your Life website in conjunction with standard clinical care to improve symptom management during chemotherapy treatment for breast cancer, which could serve as a new model for supportive oncology care.",[496,497,498],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8",{"date":417,"type":34},{"date":501,"type":34},"2026-07-15",{"date":503,"type":22},"2027-12-31",{"name":40,"class":41},{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":17,"sex":18,"minAge":512,"maxAge":513,"enrollmentInfo":514,"targetDuration":4,"studyType":23,"phases":516,"briefSummary":517,"conditions":518,"keywords":4,"overallStatus":298,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":524,"leadSponsor":526,"locationsCount":88},"100649803","a-novel-smartphone-application-for-helping-teens-stop-vaping-quitquest-vaping-r01-100649803","NCT07739706","A Novel Smartphone Application for Helping Teens Stop Vaping, QuitQuest Vaping R01","QuitQuest: Full Scale Randomized Trial of a Novel Smartphone Application to Help Teens Stop Vaping (QuitQuest Vaping R01)","Inclusion Criteria:\n\n* Age 13 to 17\n* Used ENDS at least weekly in the past 30 days\n* Wants to quit ENDS within the next 30 days\n* If concurrently using any other nicotine or tobacco products, wants to quit using them within the next 30 days\n* Interest in learning skills to quit ENDS\n* Willing to be randomly assigned to either condition\n* Resides in the United States (US) for the next 12 months\n* Has daily access to their own smartphone\n* Ability to download a smartphone app\n* Able to read in English\n* Not using other ENDS cessation interventions\n* Have not participated in our prior studies\n* No household or family member participating\n* Willingness to complete survey and biochemical assessments at 3, 6, and 12 months\n* Providing phone number(s), email, and mailing address\n\nExclusion Criteria:\n\n* Exclusion criteria are the reverse of the inclusion criteria","13 Years","17 Years",{"count":515,"type":22},1072,[25],"This clinical trial compares a novel smartphone application (app) called QuitQuest to the National Cancer Institute's (NCI's) SmokefreeTeenQuitVaping (SFTQV) app in helping teens stop vaping. Despite recent declines, data shows that 8.5% of middle school (grades 6-8) and 18.1% of high school (grades 9-12) students in the United States (US) used electronic nicotine delivery systems (ENDS; variously known as vaping, electronic \\[e\\]-cigarettes, e-cigs, mods, and tank systems that contain nicotine). Use of any tobacco product during adolescence increases risk for lifelong nicotine addiction. ENDS use, in particular, leads to severe asthma attacks, e-cigarette or vaping product use-associated lung injury (EVALI), exposure to multiple lung irritants, including volatile organic compounds, and lasting harm to adolescent brain development. Despite evidence of potential long-term harms from ENDS, to date there have been limited evidence-based therapeutic options for ENDS cessation for adolescents and young adults. Traditional methods for delivering adolescent ENDS cessation interventions (e.g., quitlines and clinics) have limited reach. QuitQuest utilizes Acceptance and Commitment Therapy (ACT), a psychological intervention that uses acceptance and mindfulness strategies, together with commitment and behavior change strategies, to increase psychological flexibility, reduce distress, and promote behavior change through mechanisms that include cultivating acceptance of internal experience and aligning behavior with personal values. The SFTQV program is based on the US Clinical Practice Guidelines, offering practical advice and support via an app delivery format. The QuitQuest app may work better than the SFTQV app in increasing vape quit rates among teens.",[519],"Tobacco-Related Carcinoma","2026-07-30",{"date":522,"type":34},"2026-08-03",{"date":376,"type":22},{"date":525,"type":22},"2031-03-31",{"name":40,"class":41},{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":534,"targetDuration":4,"studyType":23,"phases":536,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":542,"completionDateStruct":543,"leadSponsor":545,"locationsCount":110},"100587259","interpersonal-communication-training-and-vaccination-workflow-training-alone-and-in-combination-to-improve-communication-and-recommendations-about-hpv-vaccination-in-pharmacies-impact-hpv-trial-100587259","NCT06926062","Interpersonal Communication Training and Vaccination Workflow Training Alone and in Combination to Improve Communication and Recommendations About HPV Vaccination in Pharmacies, IMPACT HPV Trial","Implementing a Proactive Approach to Communicate and Teach About HPV Vaccination in Pharmacies: IMPACT HPV Study","Inclusion Criteria:\n\n* OBJECTIVE 1: Adults aged 18 years or older who live in the 50 United States (U.S.) states and Washington District of Columbia (D.C.) and are parents or guardians of children ages 9-17 are eligible to take the national survey (n ≤ 1,600, with anticipated enrollment of n = \\~1,500)\n* OBJECTIVE 2: Pharmacy staff at participating pharmacies (n ≤ 100)\n* OBJECTIVE 2: Adults aged 18 years or older whose children ages 9-17 received an HPV vaccine at one of the participating pharmacies in study year 2 (n ≤ 200)\n\nExclusion Criteria:\n\n* OBJECTIVE 1: Non-English speaking as the survey is only available for this project in English\n* OBJECTIVE 1: Parents whose index children have completed the HPV vaccine series\n* OBJECTIVE 2: Non-English speaking as the study funding only provided resources for surveys and interview materials to be available in English\n* OBJECTIVE 2: Parents whose index children have completed the HPV vaccine series",{"count":535,"type":22},1900,[25],"This clinical trial compares usual care to interpersonal communication training and vaccination workflow training, alone or in combination, for improving communication about and recommendations for human papillomavirus (HPV) and other vaccinations in pharmacies. Low HPV vaccination in the United States has placed unvaccinated children at risk of developing cancers as adults that could have been prevented. Pharmacies can be convenient for vaccination because they are open longer hours, have shorter wait times, can see patients without appointments and may cost less. However, many people are not aware that vaccination is available in pharmacies and some pharmacies lack the commitment from staff to vaccinate or may not have protocols in place for vaccination. Proactive communication approaches to recommending HPV vaccination have been shown to be effective in medical offices but have not been tested in the pharmacy setting. Interpersonal communication training incorporates the 5 A's (assess, advice, agree, assist and arrange) behavioral counseling framework to strongly recommend HPV and other vaccines and effectively answer any questions or concerns about vaccination. Vaccination workflow training establishes vaccination decision support strategies that pharmacies use to improve vaccination workflows. Interpersonal communication training and vaccination workflow training alone or in combination may improve communication and recommendations for HPV vaccination and increase HPV vaccination in pharmacies.",[539],"Human Papillomavirus-Related Carcinoma","2026-07-29",{"date":520,"type":34},{"date":245,"type":22},{"date":544,"type":22},"2027-12-01",{"name":40,"class":41},""]